Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis
|ClinicalTrials.gov Identifier: NCT00004402|
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : March 25, 2015
OBJECTIVES: I. Compare the rate of treatment failure in osteopetrosis patients receiving interferon gamma in combination with calcitriol to the rate of treatment failure in patients receiving calcitriol alone.
II. Compare the number of adverse events or clinical manifestations of disease progression occurring in these patients.
III. Assess the effects of interferon gamma on hematopoiesis, cranial nerve function, and rate of infection in these patients.
|Condition or disease||Intervention/treatment||Phase|
|Osteopetrosis||Drug: calcitriol Drug: interferon gamma||Phase 3|
PROTOCOL OUTLINE: This is a randomized, placebo controlled, open label study. Patients are randomized to one of two arms (interferon gamma in combination with calcitriol or calcitriol alone).
Arm I: Patients receive calcitriol once daily. Interferon gamma is administered by subcutaneous injection three times a week.
Arm II: Patients receive calcitriol once daily. Patients may continue treatment in the absence of toxicity and disease progression. If disease progression is diagnosed in the control group, patients will then receive interferon gamma in combination with calcitriol.
Patients are followed every 4 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Study Start Date :||November 1999|
|Estimated Study Completion Date :||June 2000|
U.S. FDA Resources
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004402
|Study Chair:||L. Lyndon Key, Jr.||Medical University of South Carolina|